Richard Nolan Townsend Sells 5,000 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $10.65, for a total transaction of $53,250.00. Following the sale, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at $1,285,401.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, August 12th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $11.53, for a total transaction of $57,650.00.
• On Wednesday, July 10th, Richard Nolan Townsend sold 26,969 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $16.50, for a total value of $444,988.50.

Lexeo Therapeutics Stock Down 1.1 %

Shares of LXEO stock traded down $0.11 during trading hours on Wednesday, reaching $10.24. 112,497 shares of the company’s stock were exchanged, compared to its average volume of 187,159. Lexeo Therapeutics, Inc. has a 1 year low of $9.00 and a 1 year high of $22.33. The stock has a market cap of $337.36 million and a PE ratio of -0.46. The company has a current ratio of 9.38, a quick ratio of 9.38 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $12.52 and its two-hundred day moving average price is $13.95.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.64) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.64). Research analysts predict that Lexeo Therapeutics, Inc. will post -2.74 EPS for the current year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of large investors have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new stake in Lexeo Therapeutics in the first quarter valued at approximately $75,000. American International Group Inc. purchased a new stake in Lexeo Therapeutics in the first quarter valued at approximately $79,000. Rhumbline Advisers boosted its position in Lexeo Therapeutics by 37.3% in the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after buying an additional 3,627 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Lexeo Therapeutics by 12.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after purchasing an additional 3,483 shares in the last quarter. Finally, Cornell University purchased a new stake in Lexeo Therapeutics in the 1st quarter worth approximately $1,980,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analyst Upgrades and Downgrades

LXEO has been the subject of several recent research reports. HC Wainwright decreased their price objective on Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Chardan Capital restated a “buy” rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday, August 14th. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Baird R W upgraded shares of Lexeo Therapeutics to a “strong-buy” rating in a report on Thursday, June 13th. Finally, Robert W. Baird began coverage on shares of Lexeo Therapeutics in a report on Thursday, June 13th. They issued an “outperform” rating and a $28.00 target price for the company. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $22.14.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.